What is the Astellas Pharma Inc. stock price forecast?

Astellas Pharma Inc. is currently trading at ¥2,132.5. View real-time AI analysis on Alpha Lenz.

What is Astellas Pharma Inc. insider trading activity?

View the latest insider trading data for Astellas Pharma Inc. on Alpha Lenz.

What is Astellas Pharma Inc.'s P/E ratio?

Astellas Pharma Inc.'s P/E ratio is 75.2.

Astellas Pharma Inc.

JPX · 4503

¥2,133-11(-0.54%)Market closed

Ask about Astellas Pharma Inc.'s future dividend policy...

Alpha Chat Insight

“Astellas Pharma Inc. trades at a P/E of 75.2 (premium valuation) with modest ROE of 3.3%. 3Y revenue CAGR of 13.8% highlights clear growth momentum.”

Ask for details →

Company Overview

Astellas Pharma Inc. is a prominent pharmaceutical company that engages in the research, development, manufacture, and marketing of pharmaceutical products across the globe. Headquartered in Japan, the company's core focus is on providing innovative treatments in areas such as oncology, immunology, and neuroscience, addressing significant unmet medical needs. Astellas works to enhance the health and quality of life for patients through its extensive portfolio of patented medicines and therapies. The company collaborates extensively with research institutions and other pharmaceutical entities to drive advancements in healthcare solutions. By continuously investing in cutting-edge research and technology, Astellas Pharma plays a critical role in the global healthcare industry, contributing to scientific innovation and patient care.

CEOMr. Naoki Okamura BSc

Websitehttps://www.astellas.com

SectorHealthcare

IndustryDrug Manufacturers - General

Employees13,643

Company Statistics

FY 2025

Profile

¥3,817,212,610,903Market Cap

¥1,912,323,000,000Revenue

0.00Shares Out

13,643Employees

Margins

81.74%Gross

12.92%EBITDA

2.10%Operating

1.63%Pre-Tax

2.65%Net

Valuation

75.22P/E

2.52P/B

2.00EV/Sales

18.06EV/EBITDA

27.83P/FCF

Growth (CAGR)

13.84%Rev 3Yr

8.01%Rev 5Yr

-32.52%Op Inc 3Yr

-30.36%Op Inc 5Yr

-25.77%Net Inc 3Yr

-23.64%Net Inc 5Yr

Returns

1.47%ROA

3.26%ROE

1.42%ROIC

Financial Health

¥188,372,000,000Cash & Cash Equivalents

¥1,637,917,000,000Net Debt

120.69%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Astellas Pharma Inc. trades at a P/E of 75.2 (premium valuation) with modest ROE of 3.3%. 3Y revenue CAGR of 13.8% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Astellas Pharma Inc. (ticker: 4503) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 13,643 employees. Market cap is $3.8T.

The current price is 2,132.5 with a P/E ratio of 75.22x and P/B of 2.52x.

ROE is 3.26% and operating margin is 2.10%. Annual revenue is $1.9T.